9-[3-(2-nitro-1-imidazoiyi)propylamino]-cyciopenteno[6]quinoline hydrochloride (nlcpq-1): a novel dna-affinic bioreductive agent as chemosensitizer. i

Oncology Research

Volumn 9, Issue 5, 1997, Pages 249-257

  Papadopoulou, Maria V ^a   Ji, Ming ^a   Rao, Mira K ^a   Bloomer, William D ^a  

^a EVANSTON HOSPITAL   (United States)

Author keywords

Bioreductive agents; Chemosensitizer; Dna affinic agents; Hypoxia; NLCPQ 1

Indexed keywords

9 (3 (2 NITRO 1 IMIDAZOLYL) PROPYLAMINO)CYCOPENTENO(B)QUINOLINE; 9-(3-(2-NITRO-1-IMIDAZOLYL)-PROPYLAMINO)CYCOPENTENO(B)QUINOLINE; ANTINEOPLASTIC AGENT; CISPLATIN; DNA; MELPHALAN; NITROIMIDAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CELL SURVIVAL; CRICETULUS; DNA ADDUCT; DRUG EFFECT; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; FEMALE; HAMSTER; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; CISPLATIN; CRICETINAE; CRICETULUS; DNA ADDUCTS; DNA, NEOPLASM; DRUG SYNERGISM; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MELPHALAN; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NITROIMIDAZOLES; QUINOLINES; TUMOR CELLS, CULTURED;

EID: 0030633994     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Moulder, J. E.; Rockwell, S. Tumor hypoxia; its impact on cancer therapy. Cancer Metastasis Rev. 5:313-341; 1987.
2. Hockel, M.; Schlenger, K.; Knoop, C.; Vaupel, P. Oxygenations of carcinomas of the uterine cervix: Evaluation by computerized O, tension measurements. Cancer Res. 51:6098-6102;1991.
3. Vaupel, P.; Schlenger, K.; Knoop, C.; Hockel, M. Oxygenations of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 51:3316-3322; 1991.
4. Gatenby, R. A.; Kassler, H. B.; Rosenblum, J. S.; Coia, L. R.; Moldofsky, P. J.; Hartz, W. H.; Broder, G. I. Oxygen distribution in squamous cell carcinoma métastases and its relationship to outcome of radiation therapy. Int. J. Radiât. Oncol. Biol. Phys. 14:831-838; 1988.
5. Hockel, M.; Knoop, C.; Schlenger, K.; Vorndran, B.; Baudmann, E.; Mitze, M.; Knapstein, P. G.; Vaupel, P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26:45-50; 1993.
6. Siemann, D. W. Modification of chemotherapy by nitroimidazoles. Int. J. Radiât. Oncol. Biol. Phys. 10:1585-1594; 1984.
7. Grau, C.; Overgaard, J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol. 13:301-309; 1988.
8. Kennedy, K. A. Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Des. 2:181-194; 1987.
9. Sartorelli, A. C. Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res. 48:775-778; 1988.
10. Papadopoulou, M. V.; Mainwaring, A. Bloomer, W. D. Potentiation of l-(2-chloroethyl)-3-cycIohexyl-l-nitrosourea's toxicity in vitro by two new bioreductive agents. Jpn. J. Cancer Res. 83:907-913; 1992.
11. Papadopoulou, M. V.; Miller, A.; Seskey, T.; Epperly, M. W.; Bloomer, W. D. Potentiation of antineoplastic drugs in vitro and in vivo by intercalating bioreductive agents. Radiât. Oncol. Invest. 1:206-217; 1993.
12. Papadopoulou, M. V.; Bloomer, W. D. Nitroheterocycliclinked acridines as DNA-targeting bioreductive agents. Drugs Future 18:231-238; 1993.
13. Murray, D.; Meyn, R. E. Enhancement of the DNA crosslinking activity of melphalan by misonidazole in vivo. Br. J. Cancer 47:195-203; 1983.
14. Bergleiter, A.; Grover, J.; Froese, E.; Goldenberg, G. J. Membrane transport, sulfhydryl levels and DNA cross-linking in Chinese hamster ovary cell mutants sensitive and resistant to melphalan. Biochem. Pharmacol. 32:293-300; 1983.
15. Holden, S. A.; Teicher, B. A.; Ara, G.; Herman, T. S.; Coleman, C. N. Enhancement of alkylating agent activity by SR-4233 in FSallC murine fibrosarcoma. J. Natl. Cancer Inst. 84:187-193:1992.
16. Doric, M. J.; Brown, J. M. Tumor-specific, scheduledependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 53:4633-4636; 1993.
17. Papadopoulous, M. V.; Rosenzweig, H. S.; Doddi, M.; Bloomer, W. D. 9-(3-(2-Nitro-l-imidazolyl)propylamino-l,2, 3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol. Res. 6:439-448; 1994.
18. Papadopoulou, M. V.; Rosenzweig, H. S.; Doddi, M.; Bloomer, W. D. S-THNLA-1 and MeN-THNLA-1. Two new bioreductive agents as radiosensitizers and selective cytotoxins of hypoxic cells. Proceedings of International Conference on Bioreductive Drug Activation, Granlibaklen Conference Center, LakeTahoe, CA, August 16-19, 1994.
19. Papadopoulou, M. V.; Ji, M.; Doddi, M.; Bloomer, W. D. 9-(3-(2-Nitro-I-imidazolyl)propyI amino)cyclopenteno(b)quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol. Res. 8: 425-434; 1996.
20. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1: A DNA-targelcd bioreductive agent as chemosensitizer in vitro and in vivo. In Vivo 10:49-58; 1996.
21. Papadopoulou, M. V.; Ji, M.; Bloomer, W. D. THNLA-1 as radio/chemosensitizer of EMT-6 tumors in mice. Br. J. Cancer 74(SuppI. XXVII):S267-S270; 1996.
22. Siemann, D. W.; Mulcahy, R. T. Sensitization of cancer chemotherapeutic agents by nitroheterocyclics. Biochem. Pharmacol. 35:111-1151986.
23. Brown, J. M.; Lemmon, M. J. Potentiation by the hypo.xic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50:7745-7749; 1990.
24. Stell, G. G.; Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy. The concept of additivity. Int. J. Radiât. Oncol. Biol. Phys. 5:85-91; 1979.
25. Rockwell, S. C.; Kallman, R. F.; Fajardo, L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl. Cancer Inst. 49: 735-749;1972.
26. Wilson, W. R.; Sum, B. G.; Denny, \V. A.; Vanzijl, P. B.; Taylor, M. L.; Chambers, D. M.; Roberts, P. B. 5-Nitro-4(N,N-dimethylamino-propylamino) quinoline (5-Nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: Comparison with nitracrine. Radiât. Res. 131:257265;1992.
27. Moulder, J. E.; Rockwell, S. Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiât. Oncol. Biol. Phys. 10: 695-712; 1984.
28. Siemann, D. W.; Sutherland, R. M. Potentiation of alkylating chemotherapy by dual function nitrofurans in multicell spheroids and solid tumors. Radiother. Oncol. 24:239-245; 1992.
29. Roizin-Towle, L.; Biaglow, J. E.; Meltzer, H. L.; Varnes, M. E. Factors associated with the preincubation effect of hypoxic cell sensitizers in vitro and their possible implications in chemosensitization. Radial. Res. 98:506-518; 1984.
30. Stratford, I. J.; Adams, G. E.; Horsman, M. R.; Kandaiya, S.; Rajaratnam, S.; Smith, E.; Williamson, C. The interaction of misonidazole with radiation, chemotherapeutic agents, or heat. Cancer Clin. Trials 3:231-236; 1980.
31. Rogan, A. M.; Hamilton, T. C.; Young, R. C.; Klecker, R. W., Jr.; Ozols, R. F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224:994-996; 1984.
32. Green, J. A.; Vistica, D. T.; Young, R. C.; Hamilton, T. C.; Rogan, A. M.; Ozols, R. F. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44:5427-5431; 1984.
33. Hirst, D. G.; Horsman, M. R.; Brown, J. M.; Hazlehurst, J. L. The effect of timing on chemosensitization by clinical levels of SR-2508. Int. J. Radiât. Oncol. Biol. Phys. 10:1641-1645; 1984.
34. Biedermann, K. A.; Wang, J.; Graham, R. P.; Brown, J. M. SR 4233 cytotoxicity and metabolism in DNA repaircompetant and repair-deficient cell cultures. Br. J. Cancer 63: 358-362;1991.